- Home
- PEN vs ELAN Comparison
PEN vs ELAN Comparison
Compare PEN & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEN | ELAN |
|---|---|---|
| Founded | 2004 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 12.2B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PEN | ELAN |
|---|---|---|
| Price | $317.69 | $22.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $360.14 | $27.89 |
| AVG Volume (30 Days) | 277.5K | ★ 3.9M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1155.56 | N/A |
| EPS | ★ 1.70 | 0.22 |
| Revenue | $1,403,665,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $14.34 | $8.21 |
| Revenue Next Year | $13.71 | $5.31 |
| P/E Ratio | $186.85 | ★ $101.66 |
| Revenue Growth | ★ 17.50 | 6.22 |
| 52 Week Low | $221.26 | $18.48 |
| 52 Week High | $362.41 | $27.98 |
Technical Indicators
Market Signals| Indicator | PEN | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 38.23 |
| Support Level | $315.31 | $21.89 |
| Resistance Level | $320.45 | $22.69 |
| Average True Range (ATR) | 1.88 | 0.71 |
| MACD | -0.36 | -0.14 |
| Stochastic Oscillator | 11.50 | 11.21 |
Price Performance
Historical ComparisonAbout PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.